Patompong Ungprasert1, Pansakorn Tanratana2, Narat Srivali3. 1. Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA; Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Electronic address: P.Ungprasert@gmail.com. 2. Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA; Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand. 3. Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Abstract
OBJECTIVE: To investigate the risk of venous thromboembolism (VTE) among patients with autoimmune hemolytic anemia (AIHA). METHODS: We conducted a systematic review and meta-analysis of observational studies that reported odds ratio, relative risk, hazard ratio or standardized incidence ratio comparing the risk of VTE in patients with AIHA versus participants without AIHA. Pooled risk ratio and 95% confidence intervals were calculated using a random-effect, generic inverse variance method of DerSimonian and Laird. RESULTS: Out of 592 potentially relevant articles, four studies (three cohort studies and one cross-sectional study) met our inclusion criteria and were included in the data analysis. The pooled risk ratio of VTE in patients with AIHA was 2.63 (95% CI, 1.37-5.05). The statistical heterogeneity of this study was high with an I(2) of 97%. CONCLUSIONS: Our study demonstrated a significantly increased risk of VTE among patients with AIHA.
OBJECTIVE: To investigate the risk of venous thromboembolism (VTE) among patients with autoimmune hemolytic anemia (AIHA). METHODS: We conducted a systematic review and meta-analysis of observational studies that reported odds ratio, relative risk, hazard ratio or standardized incidence ratio comparing the risk of VTE in patients with AIHA versus participants without AIHA. Pooled risk ratio and 95% confidence intervals were calculated using a random-effect, generic inverse variance method of DerSimonian and Laird. RESULTS: Out of 592 potentially relevant articles, four studies (three cohort studies and one cross-sectional study) met our inclusion criteria and were included in the data analysis. The pooled risk ratio of VTE in patients with AIHA was 2.63 (95% CI, 1.37-5.05). The statistical heterogeneity of this study was high with an I(2) of 97%. CONCLUSIONS: Our study demonstrated a significantly increased risk of VTE among patients with AIHA.
Authors: Megan Mullins; Xiaohui Jiang; Lauren C Bylsma; Jon P Fryzek; Heidi Reichert; Evan C Chen; Shivaani Kummar; Adam Rosenthal Journal: Blood Adv Date: 2017-05-19
Authors: Lauren C Bylsma; Anne Gulbech Ording; Adam Rosenthal; Buket Öztürk; Jon P Fryzek; Jaime Morales Arias; Alexander Röth; Sigbjørn Berentsen Journal: Blood Adv Date: 2019-10-22
Authors: Alexander Röth; Martin Bommer; Andreas Hüttmann; Dörte Herich-Terhürne; Nils Kuklik; Jan Rekowski; Veronika Lenz; Hubert Schrezenmeier; Ulrich Dührsen Journal: Blood Adv Date: 2018-10-09
Authors: Douglas B Cines; Sergei Zaitsev; Lubica Rauova; Ann H Rux; Victoria Stepanova; Sriram Krishnaswamy; Amrita Sarkar; M Anna Kowalska; Guohua Zhao; Alan E Mast; Laurence J Blumberg; Keith R McCrae; Mortimer Poncz; Jonathan J Hubbard; Michal Pyzik; Richard S Blumberg Journal: Blood Date: 2020-06-04 Impact factor: 22.113